Elite Pharmaceuticals, based in Northvale, New Jersey, develops and manufactures abuse-deterrent opioid products and employs 64 staff. Founded in 2014, it specializes in oral, controlled-release drug products and holds multiple generic licenses.
Douglas Plassche sold 800,000 shares of ELTP on 2 October at $0.62 per share, worth a total of $499K. They now own 3,500,000 ELTP shares, or a 19% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
